Home › Cancro del polmone non a piccole cellule › Kentucky › Louisville
Studi clinici su Cancro del polmone non a piccole cellule a Louisville, KY
22 studi su Cancro del polmone non a piccole cellule cercano partecipanti presso sedi a Louisville e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study of ZW251 in Participants With Advanced Solid Tumors
In reclutamentoFase 1
- Norton Cancer Institute, Louisville
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
In reclutamentoFase 1/2
- James Graham Brown Cancer Center (Melanoma/NSCLC), Louisville
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
In reclutamentoFase 3
- Baptist Health Louisville, Louisville
- Baptist Health Floyd, New Albany · a 4 mi di distanza
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
In reclutamentoFase 3
- Norton Cancer Institute Downtown, Louisville
- Norton Cancer Institute, Downtown, Louisville
- Norton Hospital, Louisville
- e altri 4
Pan-tumor MRD Study
In reclutamentoStudio osservazionale
- Baptist Health Louisville, Louisville
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
In reclutamentoFase 3
- The University of Louisville, James Graham Brown Cancer Center, Louisville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
In reclutamentoFase 1
- Norton Cancer Institute, Louisville
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
In reclutamentoFase 3
- Research Site, Louisville
- Research Site, Louisville
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
In reclutamentoFase 2/3
- University of Louisville, Louisville
- Local Institution - 007-388-A, Louisville
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
In reclutamentoFase 1/2
- Norton Cancer Institute Research, Louisville
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
In reclutamentoFase 1/2
- Norton Cancer Institute PARENT, Louisville
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
In reclutamentoFase 3
- Research Site, Louisville
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
In reclutamentoFase 1/2
- Norton Cancer Institute, Louisville
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
In reclutamentoFase 1
- Norton Cancer Institute, Louisville
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
In reclutamentoFase 2
- University of Louisville, Louisville
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
In reclutamentoFase 1
- Norton Cancer Institute /ID# 248903, Louisville
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
In reclutamentoFase 1/2
- University of Louisville, Louisville
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
In reclutamentoFase 3
- Research Site, Louisville
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
In reclutamentoFase 2
- University Medical Center, lnc.:DBA University of Louisville Hospital, Louisville
- University of Louisville, Louisville
- UofL Health Brown Cancer Center, Louisville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
In reclutamentoFase 1/2
- Research Site 115, Louisville
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
In reclutamentoFase 1
- Research Site, Louisville
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
In reclutamento
- James Graham Brown Cancer Center, Louisville
Studi su Cancro del polmone non a piccole cellule in altre città
- Houston, TX145 studi
- New York City, NY121 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH57 studi
- Washington, DC55 studi
Altri studi a Louisville
- Obesità17 studi
- Sovrappeso15 studi
- Cancro (tutti i tipi)14 studi
- Insufficienza cardiaca13 studi
- Leucemia mieloide acuta12 studi
- Mieloma multiplo12 studi
- Cancro ovarico12 studi
- Cancro al seno11 studi
- Carcinoma a cellule squamose della testa e del collo11 studi
- Cancro ai polmoni11 studi
- Melanoma10 studi
- Cancro alla prostata10 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.